Posts by: Ana Pena

News

Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory multiple myeloma patients — those ... Read more

March 23, 2018March 23, 2018

SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows

News

SELLAS Life Sciences’ Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows. Myeloma expert Guenther Koehne presented the results at the Annual ... Read more

March 2, 2018

Mouse Study Finds Potential Targets to Minimize Risks of Stem Cell Transplants

News

Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic targets to minimize the risks of ... Read more